Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa

Journal of Clinical Oncology

Volumn 27, Issue 21, 2009, Pages 3480-3488

  Mwanda, Walter O ^a   Orem, Jackson ^a   Fu, Pingfu ^a   Banura, Cecilia ^a   Kakembo, Joweria ^a   Onyango, Caren Auma ^a   Ness, Anne ^a   Reynolds, Sherrie ^a   Johnson, John L ^a   Subbiah, Vivek ^a   Bako, Jacob ^a   Wabinga, Henry ^a   Abdallah, Fatuma K ^a   Meyerson, Howard J ^a   Whalen, Christopher C ^a   Lederman, Michael M ^a   Black, Jodi ^a   Ayers, Leona W ^a   Katongole Mbidde, Edward ^a   Remick, Scot C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; PREDNISONE; PROCARBAZINE; VINCRISTINE; VIRUS RNA; ANTINEOPLASTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION; KENYA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; UGANDA; VIROTHERAPY; VIRUS REPLICATION; ADOLESCENT; AFRICA SOUTH OF THE SAHARA; B CELL LYMPHOMA; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOGENICITY; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HIV-1; HUMANS; KENYA; LOMUSTINE; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROCARBAZINE; TREATMENT OUTCOME; UGANDA; VIRUS REPLICATION; YOUNG ADULT;

EID: 70249145839     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.7641     Document Type: Article

References (50)

1. Orem J, Mwanda OW, Remick SC: AIDS-associated cancer in developing nations. Curr Opin Oncol 16:468-476, 2004
2. Otieno MW, Banura C, Katongole-Mbidde E, et al: Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. J Natl Cancer Inst 94:718-732, 2002
3. Orem J, Mwanda OW, Banura C, et al: Capacity building for the clinical investigation of AIDS malignancies. Cancer Detect Prevent 29:133-145, 2005
4. Rochford R, Feuer G, Orem J, et al: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J 82:S157-S162, 2005 (suppl 9)
5. Orem J, Mwanda OW, Remick SC: Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol 18:479-486, 2006
6. Hesseling PB, Broadhead R, Molyneux E, et al: Malawi pilot study of Burkitt lymphoma treatment. Med Pediatr Oncol 41:532-540, 2003
7. Hesseling P, Broadhead R, Mansvelt E, et al: The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer 44:245-250, 2005
8. Mwanda OW, Remick SC, Whalen C: Adult Burkitt's lymphoma in patients with and without human immunodeficiency virus infection in Kenya. Int J Cancer 92:687-691, 2001
9. Remick SC, McSharry JJ, Wolf BC, et al: Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin lymphoma. J Clin Oncol 11: 1691-1702, 1993
10. Remick SC, Sedransk N, Haase R, et al: Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies. Drugs 58:99-107, 1999 (suppl 3)
11. Remick SC, Sedransk N, Haase RF, et al: Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: Evaluation of the role of G-CSF; quality of life analysis; and long-term follow-up. Am J Hematol 66:178-188, 2001
12. Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 11:954-963, 1989
13. Gill PS, Loureiro C, Bernstein-Singer M, et al: Clinical effect of glucocorticoids on Kaposi's sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 110:937-940, 1989
14. Real FX, Krown SE, Koziner B: Steroidinduced development of Kaposi's sarcoma in a homosexual man with Burkitt's lymphoma. Am J Med 80:119-122, 1986
15. Wabinga HR, Parkin DM, Wabmire-Mangen F, et al: Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer 82:1585-1592, 2000
16. Wabinga HR, Parkin DM, Wabwire-Mangen F, et al: Cancer in Kampala, Uganda in 1989-91: Changes in incidence in the era of AIDS. Int J Cancer 54:26-36, 1993
17. Kaplan LD, Straus DJ, Testa MA, et al: Low-dose compared with standard-dosem-BACODchemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 336:1641-1648, 1997
18. Ratner L, Lee J, Tang S, et al: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19:2171-2178, 2001
19. Jaffe E, Harris N, Stein H, et al (eds): Pathology and genetics of tumours of haematopoietic and lymphoid tissues, in World Health Organization Classification of Tumors. Lyon, France, IARC Press, 2001
20. Non-Hodgkin's Lymphoma Pathologic Classification Project: NCI sponsored study of classification of non-Hodgkin's lymphoma: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
21. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998
22. World Medical Association Declaration of Helsinki: Revised Edition. Hong Kong, China, 41st World Medical Assembly, 1989
23. Council for International Organizations of Medical Sciences: International ethical guidelines for biomedical research involving human subjects. Geneva, Switzerland, Council for International Organizations of Medical Sciences, 1993
24. National Cancer Institute: National Cancer Institute Common Terminology Criteria of Adverse Events, Version 3.0. Bethesda, MD, National Cancer Institute, 2003
25. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
26. Sparano JA, Wiernik PH, Hu X, et al: Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol 14:3026-3035, 1996
27. Brown LD, Cai TT, DasGupta A: Interval estimation for a binomial proportion. Stat Sci 16:101-133, 2001
28. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Malvy D, Thiebaut R, Marimoutou C, et al: Weight loss and body mass index as predictors of HIV disease progression to AIDS in adults: Aquitane Cohort, France, 1985-1997. J Am Coll Nutr 20:609-615, 2001
30. The International Non-Hodgkin's Lymphoma Prognostic Index Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
31. Mounier N, Spina M, Gabarre J, et al: AIDSrelated non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107:3832-3840, 2006
32. Straus DJ, Huang J, Testa MA, et al: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group Protocol 142 - Low-dose vs. standard-dose m-BACOD plus granulocytemacrophage colony-stimulating factor. J Clin Oncol 16:3601-3606, 1998
33. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
34. Hughes JP: Mixed effects models with censored data with application to HIV RNA levels. Biometrics 55:625-629, 1999
35. Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data. Oxford, United Kingdom, Clarendon Press, 1994
36. Mbulaiteye SM, Katabira ET, Wabinga H, et al: Spectrum of cancers among HIV-infected persons in Africa: The Uganda AIDS-Cancer Registry Match Study. Int J Cancer 118:985-990, 2006
37. Mbulaiteye SM, Biggar RJ, Goedert JJ, et al: Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 32:527-533, 2003
38. Ziegler JL, Beckstead JA, Volberding PA, et al: Non-Hodgkin's lymphoma in 90 homosexual men: Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 311:565-570, 1984
39. Carbone A: Emerging pathways in the development of AIDS-related lymphoma. Lancet Oncol 4:22-29, 2003
40. Sparano JA, Wiernik PH, Strack M, et al: Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: A highly active regimen. Blood 81:2810-2815, 1993
41. Sparano JA, Wiernik PH, Strack M, et al: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen. Leuk Lymphoma 14:263-271, 1994
42. Boerma JT, Nunn AJ, Whitworth JA: Mortality impact of AIDS epidemic: Evidence from community sites in less developed countries. AIDS 12:S3-S14, 1998 (suppl)
43. Mbulaiteye SM, Parkin DM, Rabkin CS: Epidemiology of AIDS-related malignancies: An international perspective. Hematol Oncol Clin North Am 17:673-696, 2003
44. Little RF, Pittaluga S, Grant N, et al: Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood 101:4653-4659, 2003
45. Gonzalez CE, Adde M, Taylor P, et al: Impact of chemotherapy for AIDS-related malignancies in pediatric HIV disease. Ann NY Acad Sci 918:362-366, 2000
46. Navarro J-T, Ribera J-M, Oriol A, et al: International Prognostic Index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP: A multivariate study of 46 patients. Haematologica 83:508-513, 1998
47. Goldie SJ, Yazdanpanah Y, Losina E, et al: Cost-effectiveness of HIV treatment in resourcepoor settings: The case of Cote d'Ivoire. N Engl J Med 355:1141-1153, 2006
48. N'Galy B, Bertozzi S, Ryder RW: Obstacles to the optimal management of HIV infection/AIDS in Africa. J Acquir Immune Defic Syndr 3:430-437, 1990
49. Wakabi W: Kenya and Uganda grapple with Burkitt lymphoma. Lancet Oncol 9:319, 2008
50. Lingwood RJ, Boyle P, Milburn A, et al: The challenge of cancer control in Africa. Nat Rev Cancer 8:398-403, 2008